Cargando…
Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma
Cholangiocarcinoma (CCA) is rare cancer with the highest incidence in Eastern and Southeast Asian countries. Advanced CCA patients rely on chemotherapeutic regimens that offer unsatisfied clinical outcomes. We developed a comprehensive drug response profiling to investigate potential new drugs using...
Autores principales: | Jamnongsong, Supawan, Kueanjinda, Patipark, Buraphat, Pongsakorn, Sakornsakolpat, Phuwanat, Vaeteewoottacharn, Kulthida, Okada, Seiji, Jirawatnotai, Siwanon, Sampattavanich, Somponnat |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9563539/ https://www.ncbi.nlm.nih.gov/pubmed/36248745 http://dx.doi.org/10.1016/j.isci.2022.105182 |
Ejemplares similares
-
Novel Analytical Platform For Robust Identification of Cell Migration Inhibitors
por: Somchai, Parinyachat, et al.
Publicado: (2020) -
The Acquired Vulnerability Caused by CDK4/6 Inhibition Promotes Drug Synergism Between Oxaliplatin and Palbociclib in Cholangiocarcinoma
por: Suppramote, Orawan, et al.
Publicado: (2022) -
Nrf2 in keratinocytes modulates UVB-induced DNA damage and apoptosis in melanocytes through MAPK signaling
por: Jeayeng, Saowanee, et al.
Publicado: (2017) -
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2022) -
Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2023)